ASCO GU 2022: Breaking Down Bladder Cancer Results With Drs. Jonathan Rosenberg and Guru Sonpavde

Today-

We are reporting from the 2022 Genitourinary Cancers Symposium!

Get ready for highlights of some of the top news presented each day during the meeting—and soon Drs Jonathan Rosenberg and Guru Sonpavde will be on to share their insight on new data presented in bladder cancer.

Welcome to OncLive® News Network! I’m Gina Mauro.

Sacituzumab govitecan in combination with pembrolizumab demonstrated encouraging responses and clinical benefit rate in checkpoint inhibitor–naïve patients with metastatic urothelial cancer who progressed after prior platinum-based chemotherapy, as seen in cohort 3 of the TROPHY-U-01 trial. While there is short follow-up, biomarker evaluation is ongoing.

In cohort H of the EV-103 study, neoadjuvant enfortumab vedotin showed promising clinical activity cisplatin-ineligible patients with muscle-invasive bladder cancer. Additionally, adverse events were consistent with the known safety profile of the antibody-drug conjugate.

In the phase 3 ARIES trial, treatment with avelumab was found to have activity and good tolerability in patients with cisplatin-unfit, PD-L1–positive advanced urothelial cancer who also have poor baseline characteristics.

Long-term follow-up from the phase 3 JAVELIN Bladder 100 trial showed that avelumab plus best supportive care as first-line maintenance therapy continued to show prolonged overall survival vs avelumab/BSC alone, supporting the regimen as a standard of care for patients with advanced urothelial cancer that has not progressed on first-line platinum-containing chemotherapy.

Please be sure to check out more of our coverage from the 2022 ASCO GU meeting at OncLive.com.

That’s all for today. Tomorrow, we’ll virtually sit down with Drs Toni Choueiri and Peter Van Veldhuizen to discuss the readouts of some intriguing renal cell carcinoma studies.

Thank you for watching OncLive® News Network: On Location, I’m Gina Mauro.